Categories: News

Bry-Air Launches P80x: The Most Advanced Dehumidifier Based on MOF Technology, for the Pharmaceutical Industry

NEW DELHI, Nov. 13, 2025 /PRNewswire/ — Bry-Air, a global leader in environmental control systems, proudly announces the launch of its latest innovation, the P80x dehumidifier, especially developed for the pharmaceutical industry. This groundbreaking product marks a new era in dehumidification, with its state-of-the-art MIRACLE Next-Gen Rotor, powered by MOF (Metal-Organic Frameworks) technology.

- Advertisement -

For 35 years, the world relied on Silica Gel as the most viable desiccant for dehumidification. That era now gives way to MOFs — ultra-porous materials with dedicated molecular structures that unlock unprecedented drying performance and sustainability.

- Advertisement -

The world is waking up to the power of MOF technology, and it’s no surprise that this year’s Nobel Prize in Chemistry was awarded to three scientists for their efforts in this very domain.

- Advertisement -

The P80x dehumidifier represents a major breakthrough; this innovation surpasses the effectiveness of traditional Silica Gel desiccants, offering a giant leap forward for the industry.

- Advertisement -

Key Features of the P80x Dehumidifier Include:

- Advertisement -
  • High Performance: Achieves over 25% extra performance compared to traditional Silica Gel rotors, reducing operational costs significantly.
  • Reduced Regeneration Temperature: Operates at a lower regeneration temperature of 60°C–80°C, compared to the conventional 120°C–140°C, enhancing energy savings and system longevity.
  • Increased Energy Saving of >50% compared to conventional dehumidifiers.
  • Heat Pump Integration: The P80x is designed for seamless integration with heat pump technologies, paving the path towards Net Zero processing.

With these advancements, the P80x is not just a dehumidifier; it is a game-changer for the HVAC industry, aimed specifically at meeting the stringent requirements of the pharmaceutical sector. Bry-Air continues to lead in innovation, setting new standards in sustainability and performance.

- Advertisement -

About Bry-Air

- Advertisement -

Bry-Air is a global solution provider for complete environmental control with specialization in dehumidification and drying, plastic drying, conveying, blending, and mold dehumidification. With a strong commitment to research and development, Bry-Air provides innovative solutions that transform industries worldwide.

- Advertisement -

For more information, visit https://www.bryair.com/

- Advertisement -

Press Contact:

- Advertisement -

Kartik Tewari
Marketing Manager
Email: ktewari@pahwa.com
Phone: +91-9311664625

- Advertisement -

Photo: https://mma.prnewswire.com/media/2822166/Bry_Air_P80x_dehumidifier.jpg

- Advertisement -

 

- Advertisement -

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/bry-air-launches-p80x-the-most-advanced-dehumidifier-based-on-mof-technology-for-the-pharmaceutical-industry-302614193.html

- Advertisement -

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

7 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

7 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

7 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

7 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

7 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

7 hours ago